Biosimilars in oncology

od Tabernero, Josep
Izdano u ESMO Open (2018)

All change: closing the gender gap in oncology

od Tabernero, Josep
Izdano u ESMO Open (2018)

Two-way traffic: aligning expectations with current realities in oncology. Mid-term ESMO Presidency considerations

od Tabernero, Josep
Izdano u ESMO Open (2019)

Molecular Dissection of Microsatellite Instable Colorectal Cancer

od Vilar, Eduardo, Tabernero, Josep
Izdano 2013

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life

od Ciardiello, Fortunato, Tabernero, Josep
Izdano u ESMO Open (2016)

Back-to-back discovery, co-precision, and prevention

od Casadei, Barbara, Tabernero, Josep
Izdano u Eur Heart J Qual Care Clin Outcomes (2020)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs

od Markman, Ben, Dienstmann, Rodrigo, Tabernero, Josep
Izdano 2010

Multi-target angiokinase inhibitors to fight resistance

od Casanovas, Oriol, Salazar, Ramon, Tabernero, Josep
Izdano u Cell Cycle (2014)

Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy

od Verdaguer, Helena, Tabernero, Josep, Macarulla, Teresa
Izdano u Ther Adv Med Oncol (2016)

Optimal design of trials to demonstrate the utility of genomically‐guided therapy: Putting Precision Cancer Medicine to the test

od Dienstmann, Rodrigo, Rodon, Jordi, Tabernero, Josep
Izdano u Mol Oncol (2014)

Pushing the envelope in the mTOR pathway. The second generation of inhibitors

od Vilar, Eduardo, Perez-Garcia, Jose, Tabernero, Josep
Izdano 2011

Micromanaging the classification of colon cancer. The role of the microRNAome

od Vilar, Eduardo, Tabernero, Josep, Gruber, Stephen B.
Izdano 2011

Accomplishments in 2008 in the Treatment of Advanced Metastatic Colorectal Cancer

od Goldberg, Richard M., Meropol, Neal J., Tabernero, Josep
Izdano 2009

Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs

od Dienstmann, Rodrigo, Braña, Irene, Rodon, Jordi, Tabernero, Josep
Izdano 2011

Treatment-related mortality with aflibercept in cancer patients

od Tabernero, Josep, Hitier, Simon, Derobert, Eric, Van Cutsem, Eric
Izdano 2014

Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer

od Dienstmann, Rodrigo, De Dosso, Sara, Felip, Enriqueta, Tabernero, Josep
Izdano u Mol Oncol (2011)

How I treat gastric adenocarcinoma

od Alsina, Maria, Miquel, Josep Maria, Diez, Marc, Castro, Sandra, Tabernero, Josep
Izdano u ESMO Open (2019)

New clinical trial designs in the era of precision medicine

od Garralda, Elena, Dienstmann, Rodrigo, Piris‐Giménez, Alejandro, Braña, Irene, Rodon, Jordi, Tabernero, Josep
Izdano u Mol Oncol (2019)

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

od Tabernero, Josep, Kunzmann, Volker, Scheithauer, Werner, Reni, Michele, Shiansong Li, Jack, Ferrara, Stefano, Djazouli, Kamel
Izdano u Onco Targets Ther (2017)

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology

od Giuliani, Rosa, Tabernero, Josep, Cardoso, Fatima, McGregor, Keith Hanson, Vyas, Malvika, de Vries, Elisabeth G E
Izdano u ESMO Open (2019)